Science · Open for opinions
Will the FDA grant regulatory designation for a new ALS RNA therapy by October 31, 2026?
Consider official FDA regulatory actions for innovative RNA treatments between September 20 and October 31, 2026. 42 opinions, 64% No
- Yes — 36%
- No — 64%
Deadline: October 31, 2026 at 11:59 PM UTC · 42 opinions
Resolution rules
Consider official FDA regulatory actions for innovative RNA treatments between September 20 and October 31, 2026.
Source: www.nature.com
Frequently asked questions about this event
How is this event resolved?
Janela de apuração: de 20/09/2026 (00:00, horário de Brasília) até 31/10/2026 (23:59). Fatos, anúncios ou eventos anteriores ao início da janela não contam. Resolve como 'Sim' se a FDA (EUA) publicar autorização ou designação regulatória (como Fast Track ou Orphan Drug) para terapia de RNA voltada a formas de Esclerose Lateral Amiotrófica (ELA) até 31/10/2026, conforme registro oficial no portal fda.gov. Caso contrário, resolve como 'Não'.
How are points scored?
Points depend on the share of votes your side had when you gave your opinion. Being right earns 100 minus that share. Being wrong costs that share.
Right now No has 64% of the votes: an opinion on it that turns out right earns about 36 points, a wrong one costs about 64.